Serotonin syndrome results from excessive activation of serotonin receptors in the nervous system, on the surface of platelets, and on the vascular endothelium. The clinical manifestations are a triad of altered conscious state, autonomic dysfunction, and neuromuscular excitability. Clinical diagnostic criteria remain poorly defined and unvalidated, and there are no available investigations to confirm the diagnosis. The syndrome is caused by the administration of one or more drugs possessing serotonergic activity. Severe forms of the syndrome usually result from overdose, but can be induced by monotherapy. The exact incidence of serotonin syndrome remains unknown, but is likely to be increasing due to increased prescription of selective serotonin reuptake inhibitor antidepressants and tramadol, as well as recreational use of amphetamine-like substances. Serotonin syndrome may complicate the administration of drugs frequently used in anaesthetic practice, including pethidine and tramadol. Although the majority of cases improve with symptomatic and supportive care, severe cases need intensive care and frequently require mechanical ventilation. Neuromuscular excitability is likely to be the cause of rhabdomyolysis seen in severe cases and should be treated with benzodiazepines and muscle relaxants. Supportive therapies are required to treat hyperthermia and autonomic dysfunction. Cyproheptadine is the most commonly administered serotonergic antagonist, but is unavailable in parenteral form.
Serotonin syndrome is a cluster of symptoms and signs resulting from excessive activation of serotonin receptors. The exact incidence of the serotonin syndrome is unknown for several reasons. First, the diagnostic criteria are purely clinical and poorly validated 1 . Second, up to 85% of general practitioners prescribing selective serotonin reuptake inhibitor (SSRI) antidepressants are unaware of the serotonin syndrome 2 . Third, milder cases may go unreported by patients. Finally, the clinical features of the serotonin syndrome are relatively non-specific and may be seen in a variety of other settings.
In a post-marketing surveillance study of selective serotonin reuptake inhibitor (SSRI) antidepressants prescribed by general practitioners in the United Kingdom, the incidence of serotonin syndrome was estimated to be 4 cases per 10,000 patient months of treatment 2 .
Although the serotonin syndrome seems uncommon, the increasing use of agents that act on the serotonergic system may lead to an increase in incidence. Dispensing of oral formulations of tramadol increased from 23,000 in 2000 to 1,100,000 in 2002 3. Depression affects 1 in 16 Australians 4 , and from 1998 to 2001, prescription of the various SSRI-antidepressants increased by 13 to 66% 5 . In 2001, prescriptions for the SSRI-antidepressants outnumbered those for tricyclic antidepressants by two to one 6 . Up to 85% of the prescriptions for antidepressant drugs are written by general practitioners 7 , who may have limited knowledge of the syndrome 2 .
In this review we aim to summarize the pathogenesis and diagnostic criteria of the serotonin syndrome. Important differential diagnoses and an approach to treatment are also discussed.
PHYSIOLOGY OF THE SEROTONERGIC SYSTEM
Serotonin does not cross the blood-brain barrier and must be synthesized from dietary L-tryptophan in neurones in the pons and brainstem. The only peripheral source of serotonin is the intestinal enterochromaffin-like cells 8 . Once synthesized, serotonin is stored in vesicles within platelets and presynaptic neurones. There are at least seven different classes and 15 subpopulations of serotonin receptor, based on ligand specificity as well as their distribution and function within the body 9,10 ( Table 1 ). Receptors act either by functioning as a ligand-gated Na + /K + ion channel (5-HT 3 receptors) or by coupling to G-protein (all other subclasses studied) 11 . Second messenger systems associated with G-protein activation include cAMP (e.g. 5-HT 1A ) and phosphatidyl inositol (e.g. 5-HT 2A ). In the central nervous system (CNS) serotonin receptors have important functions in mood, alertness, sleep regulation, and thermoregulation. Low levels of serotonin in the CNS have been linked with depression, obsessive compulsive disorder, aggression, anorexia, and impaired sleep latency 12 . In the CNS, serotonergic neurones are often co-located with neurones containing neuropeptides (such as substance P and somatostatin) as well as other monoamines (such as dopamine, tyramine, and adrenaline) 12 . Serotonergic neurones comprise the major output of the ascending excitatory arousal system from the dorsal raphe nucleus of the midbrain 13 . Blockade of serotonin receptors, particularly 5-HT 2A subtypes, results in depression and drowsiness. Similarly, activation of these receptors is thought to produce the agitation observed in the serotonin syndrome 11 .
AETIOLOGY AND PATHOGENESIS
The peripheral clinical manifestations of the serotonin syndrome are similar to those seen in patients with carcinoid crisis (the severe form of the carcinoid syndrome). In carcinoid syndrome there is an increased production of serotonin from enterochromaffin-like tumour cells 14 . Central manifestations such as altered conscious state and confusion are much less common in carcinoid syndrome than the serotonin syndrome, because serotonin does not cross the blood-brain barrier. Serotonin syndrome is most commonly due to drugs that either increase the availability of serotonin at the neural endplate 15 or lead to direct receptor activation 16, 17 . Increased availability of serotonin at the endplate may occur by a number of mechanisms 8, [16] [17] [18] (Table 2 ). The clinical manifestations arise principally from activation of the 5-HT 1A and 5-HT 2A receptor subtypes. Activation of receptors in the raphe nucleus of the brainstem and frontal cortex produce alterations in conscious state 8 implicated in hypothalamic control of cardiovascular function and thermoregulation 11 . Hypertension, circulatory shock and fever have all been described as manifestations of the serotonin syndrome 10 . Peripherally, serotonin modulates vascular tone in the systemic 11 (5-HT 2A ) and pulmonary 19 (5-HT 2B ) circulations, and also increases platelet aggregation and intestinal peristalsis. Right heart failure 20 , disseminated intravascular coagulation and diarrhoea have all been described in the serotonin syndrome 10 . The precise mechanism of death from severe cases of serotonin syndrome is unknown. Case reports of fatality often include severe rhabdomyolysis, disseminated intravascular coagulation, as well as renal failure and circulatory failure [21] [22] [23] [24] [25] . It is likely that patients die from a combination of these factors.
Serotonin syndrome may be associated with drugs that are commonly prescribed for patients undergoing anaesthesia ( Table 2 ). The syndrome may result from combinations of these agents taken in therapeutic doses, or from a single agent taken in overdose 18 . Severe forms of the syndrome are usually seen in massive overdoses, or when overdose involves the presence of an uptake inhibitor such as moclobemide (MAO inhibitor) or an SSRI-antidepressant 3, 18 . However, severe cases may be seen with monotherapy 3, 24 .
CLINICAL FEATURES AND DIAGNOSIS
The diagnosis of the serotonin syndrome is clinical and confirmed when a patient displays symptoms of the syndrome following commencement or dose increase of drugs that act on the serotonergic system ( Table 3 ). The clinical features of serotonin syndrome can be described under the categories of alterations in conscious state, autonomic function, and neuromuscular status ( Table 4 ). The presence of fever, altered conscious state, autonomic instability and increased limb rigidity (especially in the lower limbs) in a patient on drugs with serotonergic activity should strongly raise the possibility of the diagnosis. The requirement for three of the eleven clinical features to be present to confirm the diagnosis is arbitrary, and based on the original suggested diagnostic criteria 29 .
The differential diagnosis for serotonin syndrome is extensive 30, [32] [33] [34] [35] [36] (Table 5 ). Because the manifestations of many of the differential diagnoses include altered conscious state, autonomic instability, or neuromuscular hyperactivity, diagnosis of serotonin syndrome can be difficult 8, 10 . Accordingly, emphasis should be placed upon obtaining an accurate history of the nature of the substances ingested. Differentiating the serotonin syndrome from neuroleptic 183 SEROTONIN SYNDROME 32, 33 has been successfully used to treat NMS but has not been shown to be of benefit for serotonin syndrome. Second, chlorpromazine has been advocated as a potential therapy for the serotonin syndrome 38 , but is contraindicated in a patient with suspected NMS. Other important differentials to entertain include sepsis and malignant hyperthermia, as their treatment also differs from that of the serotonin syndrome.
MANAGEMENT OF SEROTONIN SYNDROME
There are no prospective randomized controlled trials for the management of the serotonin syndrome 29 . Management principles, based largely on case series, include supportive measures, specific anti-serotonergic therapies, and therapies directed toward the neuromuscular excitability (Table 6 ). In a case series of 127 patients, 70% of patients with serotonin syndrome recovered in 24 hours, 40% required intensive care admission, and 25% required mechanical ventilation 10 .
Mild cases usually respond to cessation of the culprit drugs and may not require hospital admission. Patients with progressive cognitive changes, fever, autonomic instability, or neuromuscular excitability should be admitted to hospital and referred to intensive care. The mainstay of managing increased muscle tone is neuromuscular paralysis and benzodiazepine infusions. Although it is unknown how important it is to control increased muscle tone early on, it is likely to be the cause of the rhabdomyolysis seen in severe cases of the syndrome 10 . Haemodynamic support of severe cases usually requires vasopressor therapy for hypotension. Hypertension and tachycardia may also be seen, especially in milder cases. The β-blocker propranolol is usually used in such cases, partly because of its actions as a 5-HT 1A antagonist 8, 16 .
The most widely prescribed 5-HT antagonist is cyproheptadine, which can only be given orally or via nasogastric tube. Cyproheptadine acts primarily on 5-HT 2 receptors, and produces rapid (within one hour) resolution of symptoms, particularly of the CNS effects 42 . Because of recurrence of symptoms, a dose of 4-8 mg should be given every 1-4 hours 40 . Ketanserin also has anti-serotonergic properties but is not readily available in Australia. Chlorpromazine should not be routinely used to manage serotonin syndrome, especially if the patient is hypotensive and/or NMS can not be excluded. If chlorpromazine is used, careful titration of dose is suggested (starting at 25 mg) because of the potential to induce hypotension.
SEROTONIN SYNDROME AND THE ANAESTHETIST
Although the serotonin syndrome is uncommon, it may complicate the administration of drugs frequently used in anaesthetic practice. Given the lack of information regarding individual susceptibility and dose-responsiveness for activation of the syndrome, anaesthetists should consider avoiding the use of combinations of drugs known to precipitate the syndrome. This will often mean avoiding drugs such as tramadol or pethidine in patients who are taking SSRI-antidepressants or monoamine oxidase (MAO) inhibitors. It is conceivable such that a patient given tramadol intra-operatively may develop fever, tachycardia, and increased muscle tone, leading to concerns about the possibility of malignant hyperthermia. Unexplained fever, agitation, increased limb tone, or incoordination in postoperative patients receiving serotonergically acting drugs should also raise the possibility of the diagnosis. Further research is required to more accurately define the incidence of the serotonin syndrome. In addition, work is needed to determine a dose-responsiveness for its activation with administration of various drugs, particularly when they are used in com- 32, 33 History of ingestion of neuroleptic antipsychotic medications Onset and resolution over days to weeks Hypersalivation, mutism, fever, and incontinence more common Rigidity is lead pipe rather than myoclonic Agitation, confusion, hyperreflexia and myoclonus are uncommon 5 Rhabdomyolysis, leukocytosis, metabolic acidemia, and elevated hepatic transaminases more common Anticholinergic syndrome 34 History of use of TCAs or anaesthetic agents with anticholinergic activity Dry mouth, blurred vision, flushed skin, urinary retention, emesis, dizziness Prolonged QRS, ventricular arrhythmias (uncommon in serotonin syndrome), conduction blocks Hallucinations, choreo-athetoid movements relatively common Detection of agents in urine and response of features to physostigmine MAOI syndrome/cheese reaction 35 Onset is usually delayed and slow to progress Features persist following withdrawal of agent Hypertension is marked Hypotension is late and occurs following catecholamine depletion 36 Hypotension, WBC >20,000 cells/µl (uncommon in serotonin syndrome 37 ) toxic changes on blood film, detection of organisms or polymorphs in sterile body fluid. Radiographic evidence of focal infection Tetanus 36 Seen in inadequately immunized individuals following puncture wounds, lacerations or abrasions Muscle rigidity predominates, initially in the head and neck and then the back and proximal muscles. 40 cyproheptadine is a 5-HT 2 >5-HT 1 receptor antagonist only available in enteral formulation and may have anticholinergic side effects that are potentiated by MAO inhibitor 39 Methysergide 29 2 mg bd therapy described in case reports only Chlorpromazine 15, 38 25-100 mg I.M. has the advantage of I.M. administration 70% potency 5-HT 2A and 5-HT 2B receptor antagonism compared to cyproheptadine 5 should not be given if patient is hypotensive or NMS is suspected 2 Ketanserin 44 1.8 times more potent 5-HT 2A antagonist than cyproheptadine 5 has been used intravenously (10 mg boluses) for the treatment of carcinoid syndrome 31 Haemodynamic therapy Fluid and vasopressor administration for hypotension β-blocker therapy for hypertension and tachycardia blockade of sympathetic overactivity propranolol is also a 5-HT 1A antagonist 6,8 Propranolol 20 mg tds 1, 3, 6, 8 Treatment of neuromuscular abnormalities 10 Benzodiazepines Diazepam or midazolam most commonly used reduce muscle spasms and treat seizures Neuromuscular paralysis aims to counter myoclonus to prevent rhabdomyolysis
